Evidence map›Paper›PMID 41438822›Full record

ArticlePreventive medicine reports2026

Prevalence, determinants, and barriers to follow-up colonoscopy after a positive fecal immunochemical test in Qaemshahr, Iran: A population-based cross-sectional study from 2022 to 2023.

Maryam Zarrinkamar, Mahbobeh Ebrahimi, Mahnaz Zahedi, Farzaneh Amini, Mojgan Geran, Erfan Ghadirzadeh

Abstract read
In one paragraph

Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam ZarrinkamarAssistant Professor of Family Medicine, Department of Family Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mahbobeh EbrahimiAssistant Professor of Gastroenterology and Hepatology, Gut and Liver Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mahnaz ZahediMD, MPH Candidate, Mazandaran University of Medical Sciences, Sari, Iran.
Farzaneh AminiDepartment of Biostatistics and Epidemiology, Student Research Committee, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Mojgan GeranAssistant Professor of Family Medicine, Department of Family Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Erfan GhadirzadehGastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Fecal Immunochemical Test (FIT) screening reduces mortality by detecting early-stage colorectal cancer (CRC), but its success depends on follow-up colonoscopy after a positive result. Follow-up rates vary widely, influenced by several barriers, which need to be addressed. Thus, the present study aimed to assess the prevalence, determinants, and barriers to a follow-up colonoscopy after a positive FIT result. Methods: This cross-sectional study evaluated FIT-based CRC screening from April 2022 to March 2023 in Qaemshahr, Iran. Positive FIT results triggered follow-up colonoscopies. Data on colonoscopy results and reasons for non-compliance were collected. Logistic regression was conducted to identify factors affecting follow-up rates. Results: Of 14,784 screened, 294 (1.98 %) had positive FIT results; only 167 (56.80 %) underwent colonoscopy, with 73.65 % showing no abnormalities. Barriers included cost (18.89 %), perceived unimportance (41.73 %), fear (34.64 %), and lack of social support and appointment difficulties (4.72 %). Lower education levels (OR from 15.46 for illiterate to 3.79 for high school level, compared to university/college level), and asymptomatic status (OR: 1.86; 95 %CI: 1.01, 3.41) significantly reduced follow-up odds; while other demographics showed no association. Conclusion: This study reveals a concerning 56.80 % follow-up colonoscopy rate among FIT-positive patients, driven by cost, communication gaps, fear, and educational disparities.

Indexed as

ColonoscopyColorectal neoplasmsFecal immunochemical testScreening

Identifiers

PMID41438822
PMCPMC12719735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.